Bacil Pharma Limited
Bombay Stock ExchangeTotal Valuation
Bacil Pharma Limited carries a market capitalization of 543.98M, placing it among publicly traded companies globally. Its enterprise value stands at 649.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 543.98M |
| Enterprise Value | 649.71M |
Share Statistics
Bacil Pharma Limited currently has 14.35M shares outstanding.
| Shares Outstanding | 14.35M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Bacil Pharma Limited trades at a trailing price-to-earnings ratio of 48.79.
| PE Ratio | 48.79 |
| PS Ratio | N/A |
| PB Ratio | 4.69 |
| P/TBV Ratio | 2.64 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Financial Position
Bacil Pharma Limited maintains a current ratio of 0.68, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.68 |
| Quick Ratio | 0.22 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | 6.82 |
| Return on Assets (ROA) | 5.07 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 6.16 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Bacil Pharma Limited has paid -3.53M in income taxes, reflecting an effective tax rate of 50.17.
| Income Tax | -3.53M |
| Effective Tax Rate | 50.17 |
Stock Price Statistics
Bacil Pharma Limited's stock has gained approximately 0.85151676% over the past 52 weeks. The 50-day moving average sits at 49.35, while the 200-day moving average is 44.25.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.85151676% |
| 50-Day Moving Average | 49.35 |
| 200-Day Moving Average | 44.25 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -2.45M, while operating income came in at -2.45M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -2.45M |
| Pretax Income | 9.90M |
| Net Income | 13.43M |
| EBITDA | -2.45M |
| EBIT | -2.45M |
| Earnings Per Share (EPS) | 0.98 |
Balance Sheet
Total book value stands at 139.70M, with working capital of -8.27M providing operational flexibility.
| Cash & Cash Equivalents | 5.69M |
| Total Debt | N/A |
| Net Debt | -5.68M |
| Equity (Book Value) | 139.70M |
| Book Value Per Share | 10.17 |
| Working Capital | -8.27M |
Scores
Bacil Pharma Limited posts an Altman Z-Score of 15.18, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 15.18 |